Skip to content

Clinical Outcomes of Patients Implanted With the RxSight Light Adjustable Lens (LAL)

Clinical Outcomes of Patients Implanted With the RxSight Light Adjustable Lens (LAL)

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06488066
Enrollment
0
Registered
2024-07-05
Start date
2021-08-13
Completion date
2022-01-01
Last updated
2024-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract, Pseudophakia

Brief summary

The objective of this investigator initiated study (IIT-002) is to collect data on commercial patients implanted with the RxSight Light Adjustable Lens (LAL).

Interventions

OTHERData collection

Collection of clinical data from groups of patients already implanted with the light adjustable lens (LAL) and have completed light treatments.

Sponsors

Vance Thompson Vision
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Sign a written Informed Consent Document * Implanted commercially with the LAL and completed LDD light treatments

Exclusion criteria

* Previous corneal or intraocular surgery other than removal of cataract and implantation of the LAL

Design outcomes

Primary

MeasureTime frameDescription
Manifest refractionPre operatively and immediately post operativelyA qualified ophthalmologist, optometrist, or a trained ophthalmic technician should obtain the refraction, in 0.25D steps, in a calibrated refraction lane. If the subject has a current pair of glasses for distance vision, they can be measured with a lensometer, and these measurements are used as the beginning approximate refraction

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026